Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 741

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 741
---

    following the change of control, then upon such termination, all of the participant’s awards in effect on the date of such
    termination will vest in full or be deemed earned in full.

If
the purchaser, successor, or surviving entity does not assume the awards or issue replacement awards, then immediately prior to the change
of control date, unless the Administrator otherwise determines:

    ●
    Each
    stock option or SAR then held by a participant will become immediately and fully vested, and all stock options and SARs will be cancelled
    on the change of control date in exchange for a cash payment equal to the excess of the change of control price of the shares of
    common stock over the purchase or grant price of such shares under the award.

    ●
    Unvested
    restricted stock and RSUs (that are not performance awards) will vest in full.

    ●
    All
    performance shares, performance units and cash incentive awards for which the performance period has expired will be paid based on
    actual performance, and all such awards for which the performance period has not expired will be cancelled in exchange for a cash
    payment equal to the amount that would have been due under such awards, valued assuming achievement of target performance goals at
    the time of the change of control, prorated based on the number of full months elapsed in the performance period.

    ●
    All
    unvested dividend equivalent units will vest (to the same extent as the award granted in tandem with such units) and be paid.

    ●
    All
    other unvested awards will vest and any amounts payable will be paid in cash.

Term
of Plan

Unless
earlier terminated by our board of directors, the 2022 Omnibus Plan will terminate on, and no further awards may be granted, after the
tenth (10th) anniversary of its effective date.

Termination
and Amendment of Plan

Our
board of directors or the Administrator may amend, alter, suspend, discontinue, or terminate the 2022 Omnibus Plan at any time, subject
to the following limitations:

    ●
    Our
    board of directors must approve any amendment to the 2022 Omnibus Plan if we determine such approval is required by prior action
    of our board of directors, applicable corporate law, or any other applicable law;

78

    ●
    Stockholders
    must approve any amendment to the 2022 Omnibus Plan, which